Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II

Journal of Hypertension

Volumn 25, Issue 8, 2007, Pages 1543-1553

  Boutitie, Florent ^a,b,c   Oprisiu, Roxana ^d   Achard, Jean Michel ^e   Mazouz, Hakim ^d   Wang, Jiguang ^g   Messerli, Franz H ^h   Gueyffier, François ^f   Fournier, Albert ^d  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

^f INSERM   (France)

^g SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^h ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Antihypertensive drugs; Meta analysis; Meta regression; Nonangiotensin II type 1 receptors of angiotensin; Risk reduction beyond blood pressure; Stroke prevention

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LONG ACTING DRUG; NIFEDIPINE; PLACEBO; SHORT ACTING DRUG; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; DRUG MEGADOSE; HEART FAILURE; HUMAN; HYPERTENSION; META ANALYSIS; METHODOLOGY; PHARMACODYNAMICS; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION; STROKE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 34447301224     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32814a5ae5     Document Type: Article

References (86)

1. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease, Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilutio bias. Lancet 1990; 335:765-774.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
3. Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, MacMahon S. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003; 21:707-716.
4. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358:1305-1315.
5. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA. Blood pressure, stroke and coronary heart disease, Part 2. Short term reduction in blood pressure overview of randomized drug trials in their epidemiological context. Lancet 1990; 335:827-838.
6. Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke 2004; 35:1024-1034.
7. Veteran Administration Hospital study group. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 1967; 202:1028-1034.
8. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older patients with isolated Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
9. Veteran Administration Hospital study group. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 1970; 213:1143-1152.
10. MRC Working Party. MRC trial of treatment of mild hypertension. Principal results. BMJ 1985; 291:97-104; Meta-analysis BMJ 1988, 1296:1565-1570.
11. Brown MJ, Brown J. Does angiotensin II protect against strokes? Lancet 1986; 2:427-429.
12. Fernandez L, Spencer D, Kaczmar T. Angiotensin II decreases mortality rate in gerbils with unilateral carotid ligation. Stroke 1986; 17:82-85.
13. Kaliszewski C, Fernandez L, Wicke J. Differences in mortality rate between abrupt and progressive carotid ligation in the gerbil: role of endogenous angiotensin II. J Cerebral Blood Flow and Metab 1988; 8:149-154.
14. 2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation. J Cardiovasc Pharmacol 1994; 24:937-940.
15. Dai W, Funk A, Herdegen T, Unger T, Culman J. Blockade of central angiotensin AT1 receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 1999; 30:2391-2399.
16. 2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005; 19:617-619.
17. 1-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil. JRAAS 2001; 2:103-106.
18. Fagan SC, Kozak A, Hill WD, Pollock DM, Xu L, Johnson MH, et al. Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. J Hypertens 2006; 24:535-539.
19. Faure S, Oudart N, Javellaud J, Fournier A, Warnock DG, Achard JM. Synergistic protective effect of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunction in the gerbil. J Hypertens 2006; 24:2255-2261.
20. Messerli FH, Grossman E, Lever AF. Do thiazide diuretics confer specific protection against strokes? Arch Intern Med 2003; 163:2557-2560.
21. 2) receptors. A hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 2004; 45:1143-1147.
22. HDFP. Five-year findings of the Hypertension Detection and Follow-up Program. I: Reduction in mortality of persons with high blood pressure, including mil hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA 1979; 242:2562-2571.
23. Multiple Risk Factor Intervention Trial (MRFIT) reseach group. Risk factor changes and mortality results. JAMA 1982; 248:1465-1477.
24. Magy L, Vincent F, Faure S, Messerli FH, Wang JG, Achard JM, Fournier A. The renin-angiotensin systems: evolving pharmacological perspectives for cerebroprotection. Curr Pharm Des 2005; 11:3275-3291.
25. Kaplan NM. Treatment of hypertension: drug therapy. In: Clinical hypertension, 7th ed. Philadelphia: Lippincott, Williams and Wilkins; 2002. pp. 238-338.
26. Grossman E, Messerli FH. Effect of calcium antagonists on plasma norepinephrine levels, heart rate and blood pressure. Am J Cardiol 1997; 80:1453-1458.
27. Binggeli C, Corti R, Sudano I, Luscher TF, Noll G. Effect of chronic calcium channel blockade on sympathetic nerve activity in hypertension. Hypertension 2002; 39:392-396.
28. Lindqvist M, Kahan T, Melcher A, Hjemdahl P. Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension. Hypertension 1994; 24:287-296.
29. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340:1321-1328.
30. Struck J, Muck P, Trubger D, Handrock R, Weidinger G, Dendorfer A, Dodt C. Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects. J Hypertens 2002; 20:1143-1149.
31. Fogari R, Mugellini A, Zoppi A, Corradi L, Rinaldi A, Derosa G, Preti P. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens 2003; 16:596-599.
32. Jakobsen J, Glaus L, Graf P, Degen P, Maurice NP, Bellet M, Ménard J. Unmasking of the hypotensive effect of nifedipine in normotensives by addition of the angiotensin converting enzyme inhibitor benazepril. J Hypertens 1992; 10:1045-1051.
33. Boutouyrie P, Bussy C, Lacolley P, Girerd X, Laloux B, Laurent S. Association between local pulse pressure, mean blood pressure, and large-artery remodeling. Circulation 1999; 100:1387-1393.
34. Hackenthal E, Nobiling R. Renin secretion and its regulation. In: Swales JD, editor. Textbook of hypertension. Oxford: Blackwell Scientific Publishers; 1994. pp. 232-243.
35. Noel B, Del Re G, Capone P, Brunner HR, Nussberger J. Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. J Cardiovasc Pharmacol 1996; 28:252-258.
36. Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruytere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet 1985; i:1349-1354.
37. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults. Principal results. BMJ 1992; 304:405-412.
38. PATS Collaborating Group. Post-stroke antihypertensive study. Chinese Med J 1995; 108:710-717.
39. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Page V, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14:1237-1245.
40. Staessen J, Fagard R, Thys L, Celis H, Arabidze GG, Birkenhager WH, et al., for the Syst-Eur trial investigators. Randomized double blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-764.
41. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998; 16:1823-1829.
42. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875-886.
43. IPPSH Collaborative Group. Cardiovascular risk and risk factor in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985; 3:379-392.
44. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 1993; 24:543-548.
45. Erikson S, Olofson BO, Wester PO, for the TEST Study Group. Atenolol in secondary prevention after stroke. Cerebrovasc Dis 1995; 5:21-25.
46. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, for the Heart Outcome Prevention Evaluation (HOPE) study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153.
47. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
48. Fox KM, Remme WJ. The EUROPEAN trial on reduction of cardiac events with Perindopril in stable coronary artery disease investigators: efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised double blind placebo multicenter trial. Lancet 2003; 362:782-788.
49. Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Menard J. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004; 328:495-498.
50. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058-2068.
51. ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA 2000; 283:1967-1975.
52. Hansson L, Lindholm L, Ekbom T, Dahlöf B, for the STOP2 Hypertension - 2 Study Group. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity, the Swedish Trial in old patients with hypertension - 2 study. Lancet 1999; 354:1751-1756.
53. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359-365.
54. Hansson L, Lindholm L, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPPP) randomised trial. Lancet 1999; 353:611-616.
55. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289:2073-2082.
56. Wilhemsen L, Berglund G, Elingeldt D. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987; 5:561-572.
57. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106:2422-2427.
58. Dahlöf B, Devereux R, Kjeldsen S, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
59. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288:2981-2997.
60. Wing LMH, Reid CM, Ryan P, Beilen L, Brown MA, Jennings GL, et al., for the ANBP2 study group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for the treatment of hypertension in the elderly. N Engl J Med 2003; 348:583-592.
61. Hansson L, Zanchetti A, Carruthers G, Dahlöf B, Elmfeldt D, Julius S, et al., for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762.
62. Estacio R, Jeffers B, Hiatt W, Biggi S, Gifford N, Schrier R. The effect of nisoldipine as compared with enalapril on cardiovascular events in patients with NIDD and hypertension. N Engl J Med 1998; 338:645-652.
63. Holman R, for the UKPDS group. Efficacy of atenolol and captopril in reducing the risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ 1998; 317:713-720.
64. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23:2157-2172.
65. Dahlöf B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338:1281-1285.
66. Borhani N, Mercuri M, Borhani P, Buckalew V, Canossa-Terris M, Carr A, et al. Final outcome results of the multicenter Isradipine diuretic atherosclerosis study (MIDAS). A randomized controlled trial. JAMA 1996; 276:785-791.
67. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW,Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international nifedipine GITS study: intervention as a Goal in Hypertension treatment (INSIGHT). Lancet 2000; 356:366-372.
68. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.
69. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36:1218-1226.
70. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
71. Rosei E, Dal Palu C, Leonetti G, Magnani B, Pessina A, Zanchetti A. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. VHAS Investigators. J Hypertens 1997; 15:1337-1344.
72. Tatti P, Pahor M, Byington R, Di Mauro P, Garisco R, Strollo F. Outcome results of the fosinopril-amlodipine cardiovascular events trial (FACET) in hypertensive patients with hypertension and NIDDM. Diabetes Care 1998; 21:567-603.
73. Bulpitt CJ, Beckett NS, Cooke J, Dumitrascu DL, Gil-Extremera B, Nachev C, et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21:2409-2417.
74. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19:251-253.
75. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289:2534-2544.
76. Cochran WG. The comparison of percentages in matched samples. Biometrika 1950; 37:256-266.
77. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
78. Available at: http://www.spc.univ-lyon1.fr/easyma.net. Accessed: 11 November 2005
79. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-1756.
80. Strandberg TE. Secondary prevention of stroke is important: but all hypertensive drugs are not created equal? Stroke 2005; 36:1225-1226.
81. Samy Modeliar S. Fever study: a trial further supporting the concept of a blood pressure-independent stroke protective effect by dihydropyridines. J Hypertens 2006; 24:1215-1216.
82. Blood Pressure Lowering Treatment Trialists' Collaboration (BPLT). Effect of ACE inhibitors, calcium antagonists and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 356:1955-1964.
83. Fournier A, Achard JM, Boutitie F, Mazouz H, Mansour J, Oprisiu R, et al. Is the angiotensin II type 2 receptor cerebroprotective? Curr Hypertens Rep 2004; 6:182-189.
84. Achard JM, Fournier A, Mazouz H, Caride VJ, Penar PL, Fernandez L. Protection against ischemia: a physiological function of the renin angiotensin system. Biochem Pharmacol 2001; 62:261-271.
85. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS. Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 1989; 36:690-695.
86. Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004; 110:843-848.